Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Capital Expenditures (2017 - 2023)

Rhythm Pharmaceuticals (RYTM) has disclosed Capital Expenditures for 6 consecutive years, with -$1000.0 as the latest value for Q4 2023.

  • On a quarterly basis, Capital Expenditures changed 0.0% to -$1000.0 in Q4 2023 year-over-year; TTM through Dec 2023 was $47000.0, a 83.27% decrease, with the full-year FY2025 number at $953000.0, changed N/A from a year prior.
  • Capital Expenditures was -$1000.0 for Q4 2023 at Rhythm Pharmaceuticals, down from $1000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $2.3 million in Q2 2019 to a low of -$1000.0 in Q4 2022.
  • A 4-year average of $296214.3 and a median of $81500.0 in 2021 define the central range for Capital Expenditures.
  • Biggest YoY gain for Capital Expenditures was 958.33% in 2022; the steepest drop was 101.47% in 2022.
  • Rhythm Pharmaceuticals' Capital Expenditures stood at $259000.0 in 2019, then tumbled by 73.75% to $68000.0 in 2021, then tumbled by 101.47% to -$1000.0 in 2022, then changed by 0.0% to -$1000.0 in 2023.
  • Per Business Quant, the three most recent readings for RYTM's Capital Expenditures are -$1000.0 (Q4 2023), $1000.0 (Q3 2023), and $47000.0 (Q1 2023).